In CCA, silencing CEACAM6 has been shown to significantly increase E-cadherin expression, decrease N-cadherin expression, downregulate TWIST transcription factors at both protein and mRNA levels, and reduce phosphorylation levels of molecules involved in the Src/PI3K/Akt signaling pathway [27]. The gene discussed is CEACAM6; the disease is cholangiocarcinoma.